Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin

doxorubicin

  • Open Access
    Recombinant Methioninase Is Selectively Synergistic With Doxorubicin Against Wild-type Fibrosarcoma Cells Compared to Normal Cells and Overcomes Highly-Doxorubicin-resistant Fibrosarcoma
    SEI MORINAGA, QINGHONG HAN, KOHEI MIZUTA, BYUNG MO KANG, MOTOKAZU SATO, MICHAEL BOUVET, NORIO YAMAMOTO, KATSUHIRO HAYASHI, HIROAKI KIMURA, SHINJI MIWA, KENTARO IGARASHI, TAKASHI HIGUCHI, HIROYUKI TSUCHIYA, SATORU DEMURA and ROBERT M. HOFFMAN
    Anticancer Research August 2024, 44 (8) 3261-3268; DOI: https://doi.org/10.21873/anticanres.17144
  • You have access
    PEMF Potentiates Doxorubicin-induced Late G2 Arrest in MDA-MB-231 Breast Cancer Cells
    SUNG-HUN WOO, BYUNG CHUL JUNG, JUN-YOUNG KIM, YONG-HEUM LEE and YOON SUK KIM
    Anticancer Research July 2024, 44 (7) 2837-2846; DOI: https://doi.org/10.21873/anticanres.17096
  • You have access
    Mesna, Doxorubicin, Ifosfamide and Dacarbazine (MAID) Combination Chemotherapy for Retroperitoneal Sarcoma: A Single-center Experience
    YUDAI ISHIYAMA, TORU INAKAWA, MAKI YOSHINO, KOICHI NISHIMURA, TOSHIHIDE HORIUCHI, HIROKI ISHIHARA, DAISUKE TOKI and TSUNENORI KONDO
    Anticancer Research July 2024, 44 (7) 3213-3220; DOI: https://doi.org/10.21873/anticanres.17137
  • You have access
    Doxorubicin as Risk Factor for Fascial Dehiscence After CRS-HIPEC for Peritoneal Metastases
    ELISA PIZZOLATO, CAROLA CENZI, MARCO TONELLO, PIERLUIGI PILATI and ANTONIO SOMMARIVA
    Anticancer Research April 2024, 44 (4) 1553-1557; DOI: https://doi.org/10.21873/anticanres.16952
  • You have access
    Terpyridine Functionalized Cyclodextrin Nanoparticles as Carriers for Doxorubicin: Analysis of In Vitro Antiproliferative Activity
    MAURIZIO VIALE, NADIA BERTOLA, ROBERTA PANEBIANCO and GRAZIELLA VECCHIO
    Anticancer Research December 2023, 43 (12) 5409-5414; DOI: https://doi.org/10.21873/anticanres.16744
  • Open Access
    Antitumor Activity of Symmetrical Selenoesters in Doxorubicin Resistant Breast Cancer
    BALINT RACZ, ERZSEBET KRISTOF, ANNAMARIA KINCSES, ENRIQUE DOMINGUEZ-ALVAREZ and GABRIELLA SPENGLER
    Anticancer Research November 2023, 43 (11) 4865-4872; DOI: https://doi.org/10.21873/anticanres.16683
  • Open Access
    Elimination of Axillary-Lymph-Node Metastases in a Patient With Invasive Lobular Breast Cancer Treated by First-line Neo-adjuvant Chemotherapy Combined With Methionine Restriction
    YUTARO KUBOTA, QINGHONG HAN, NORIYUKI MASAKI, CHIHIRO HOZUMI, KAZUYUKI HAMADA, YUSUKE AOKI, KOYA OBARA, TAKUYA TSUNODA and ROBERT M. HOFFMAN
    Anticancer Research December 2022, 42 (12) 5819-5823; DOI: https://doi.org/10.21873/anticanres.16089
  • You have access
    Effect of Chloroquine on Doxorubicin-induced Apoptosis in A549 Cells
    KEISUKE SATO, NATSUKI OTA, SHOYA ENDO, AKIFUMI NAKATA, HIROSHI YAMASHITA and RYOSUKE TATSUNAMI
    Anticancer Research August 2022, 42 (8) 4025-4035; DOI: https://doi.org/10.21873/anticanres.15899
  • You have access
    Poly(Alkyloxyethylene-Lactate Phosphate) for Delivery of Doxorubicin: Synthesis and Characterization
    KANJI YOSHIKAWA, TERUKI NII, KOLIO TROEV, KIMIKO MAKINO and ISSEI TAKEUCHI
    Anticancer Research April 2022, 42 (4) 1801-1811; DOI: https://doi.org/10.21873/anticanres.15656
  • You have access
    The Natural Estrogen Receptor Beta Agonist Silibinin as a Promising Therapeutic Tool in Diffuse Large B-cell Lymphoma
    ELENA ORTONA, SILVIA L. LOCATELLI, MARIA TERESA PAGANO, BARBARA ASCIONE, GIUSEPPA CAREDDU, MARIA LUISA DUPUIS, MATTEO MARCONI, CARMELO CARLO-STELLA, WALTER MALORNI, PAOLA MATARRESE and MARINA PIERDOMINICI
    Anticancer Research February 2022, 42 (2) 767-779; DOI: https://doi.org/10.21873/anticanres.15535

Pages

  • Next
  • 1
  • 2
  • 3
  • 4
  • 5
Anticancer Research

© 2025 Anticancer Research

Powered by HighWire